Combination of the Akt inhibitor MK-2206 and either EGFR/HER2 targeted therapy [erlotinib (a.k.a tarceva, an EGFR inhibitor from Genenetec/OSI/Roche) or lapatinib (a.k.a. tykerb, a dual EGFR and HER2 inhibitor from GSK) or chemotherpapeutic drugs (doxorubicin, camptothechin, gemcitabine, 5-flurouracil, docetaxel or carboplatin resulted in synergistic responses in lung (NCI-H460) and ovarian (A2780) cancer cell lines. This evidence concerns the gene AKT1 and cancer.